Literature DB >> 11108991

An N-methyl-D-aspartate antagonist, MK-801, preferentially reduces electroconvulsive shock-induced phosphorylation of p38 mitogen-activated protein kinase in the rat hippocampus.

Y M Ahn1, S W Oh, U G Kang, J Park, Y S Kim.   

Abstract

Electroconvulsive shock (ECS) activates the mitogen-activated protein kinase (MAPK) family in the rat hippocampus, but the signaling pathways for this activation are not well understood. We investigated whether N-methyl-D-aspartate (NMDA) receptor mediated signaling is involved in the phosphorylation-activation of the MAPK family. The NMDA receptor antagonist, MK-801, dose-dependently reduced ECS-induced phosphorylation of p38 and its upstream kinase MKK6 up to 1 mg/kg. MK-801 also reduced the phosphorylation of ERK1/2 and MEK1, but only at high dosage, 2 mg/kg. Moreover, the reduction in the phosphorylation of p38 and MKK6 was greater than that of ERK1/2 and MEK1. Our results suggest that ECS activates p38 and ERK1/2 partly through an NMDA receptor-mediated signaling system in the rat hippocampus and that NMDA receptor mediated signaling is more responsible for the activation of the MKK6-p38 pathway than the MEK1-ERK pathway.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11108991     DOI: 10.1016/s0304-3940(00)01632-3

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  2 in total

1.  Electroconvulsive seizure inhibits the mTOR signaling pathway via AMPK in the rat frontal cortex.

Authors:  Se Hyun Kim; Hyun Sook Yu; Seonghoo Huh; Ung Gu Kang; Yong Sik Kim
Journal:  Psychopharmacology (Berl)       Date:  2021-10-30       Impact factor: 4.530

2.  Rapid activation of the extracellular signal-regulated kinase 1/2 (ERK1/2) signaling pathway by electroconvulsive shock in the rat prefrontal cortex is not associated with TrkB neurotrophin receptor activation.

Authors:  Henrik H Hansen; Tomi P J Rantamäki; Marianne H Larsen; David P D Woldbye; Jens D Mikkelsen; Eero H Castrén
Journal:  Cell Mol Neurobiol       Date:  2007-08       Impact factor: 5.046

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.